Search

everythinglearnresearchcommunity

for

Search:↓

Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.

JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.

Alkylation of human hair keratin allows for adjustable drug release rates in hydrogels for medical use.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.

An over-the-counter vitamin/mineral supplement improved hair loss and blood sugar control in a woman with non-classic 11-hydroxylase deficiency.

Both enzyme forms can sulfate minoxidil.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.

CYLD deficiency in skin tumors disrupts hair follicle cell processes and protein secretion.

New compounds called benzoquinolinones may treat conditions linked to excess DHT.

Scientists made new substances that can block an enzyme linked to prostate issues and hair loss, with potential for creating a new treatment.

The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.

Lysine carboxymethyl cysteinate (LCC) protects skin from UVB damage by activating autophagy.

Blocking 11β-HSD1 reduces stress hormone damage in hair growth cells.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Blocking a specific enzyme can reduce the negative impact of stress hormones on hair growth cells.

Tislelizumab can cause cutaneous lupus erythematosus.

The diphosphonate was the most effective at preventing calcification in rats.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

A substance called Compound 2g can strongly block STS (a hormone-related enzyme) without affecting estrogen levels, making it potentially good for treating breast cancer.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Baricitinib might help treat hair loss in lupus patients, but more research is needed.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Sonidegib effectively treated basal cell carcinoma in a patient with lupus without worsening lupus symptoms.